Resistance of young gelatinase B-deficient mice to experimental autoimmune encephalomyelitis and necrotizing tail lesions

被引:236
作者
Dubois, B
Masure, S
Hurtenbach, U
Paemen, L
Heremans, H
van den Oord, J
Sciot, R
Meinhardt, T
Hämmerling, G
Opdenakker, G
Arnold, B
机构
[1] Katholieke Univ Leuven, Rega Inst Med Res, Lab Mol Immunol, B-3000 Louvain, Belgium
[2] German Canc Res Ctr, Lab Mol Immunol, D-69120 Heidelberg, Germany
[3] Katholieke Univ Leuven, Lab Histo & Cytochem, B-3000 Louvain, Belgium
[4] Katholieke Univ Leuven, Neuropathol Lab, B-3000 Louvain, Belgium
关键词
D O I
10.1172/JCI6886
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Regulated expression of matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) plays a role in various physiological processes. To determine in vivo how unbalanced expression of these factors can promote or affect the course of pathologies, we knocked out the mouse gelatinase B gene by replacing the catalytic and zinc-binding domains with an antisense-oriented neomycin resistance gene. Adult gelatinase B-deficient mice and wild-type controls could be induced to develop experimental autoimmune encephalomyelitis (EAE) with similar scores for neurologic disease, blood-brain barrier permeability, and central nervous system histopathology. However, whereas diseased control animals showed necrotizing tail lesions with hyperplasia of osteocartilaginous tissue, adult gelatinase B-deficient mice were resistant to this tail pathology. Gelatinase B-deficient mice younger than 4 weeks of age were significantly less susceptible to the development of EAE than were age matched controls and, even as they aged, they remained resistant to tail lesions. These data illustrate that gelatinase B expression plays a role in the development of the immune system and that, in ontogenesis, the propensity to develop autoimmunity is altered by the absence of this MMP.
引用
收藏
页码:1507 / 1515
页数:9
相关论文
共 59 条
  • [1] Ågren MS, 1998, BRIT J SURG, V85, P68
  • [2] Backstrom JR, 1996, J NEUROSCI, V16, P7910
  • [3] BAKER D, 1992, CLIN EXP IMMUNOL, V90, P124
  • [4] PROTEINASE-INHIBITORS SUPPRESS THE DEVELOPMENT OF EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS
    BROSNAN, CF
    CAMMER, W
    NORTON, WT
    BLOOM, BR
    [J]. NATURE, 1980, 285 (5762) : 235 - 237
  • [5] Matrix metalloproteinases degrade myelin basic protein
    Chandler, S
    Coates, R
    Gearing, A
    Lury, J
    Wells, G
    Bone, E
    [J]. NEUROSCIENCE LETTERS, 1995, 201 (03) : 223 - 226
  • [6] Matrix metalloproteinase expression during experimental autoimmune encephalomyelitis and effects of a combined matrix metalloproteinase and tumour necrosis factor-alpha inhibitor
    Clements, JM
    Cossins, JA
    Wells, GMA
    Corkill, DJ
    Helfrich, K
    Wood, LM
    Pigott, R
    Stabler, G
    Ward, GA
    Gearing, AJH
    Miller, KM
    [J]. JOURNAL OF NEUROIMMUNOLOGY, 1997, 74 (1-2) : 85 - 94
  • [7] Enhanced expression of MMP-7 and MMP-9 in demyelinating multiple sclerosis lesions
    Cossins, JA
    Clements, JM
    Ford, J
    Miller, KM
    Pigott, R
    Vos, W
    VanderValk, P
    DeGroot, CJA
    [J]. ACTA NEUROPATHOLOGICA, 1997, 94 (06) : 590 - 598
  • [8] The expression of tissue-type plasminogen activator, matrix metalloproteases and endogenous inhibitors in the central nervous system in multiple sclerosis: Comparison of stages in lesion evolution
    Cuzner, ML
    Gveric, D
    Strand, C
    Loughlin, AJ
    Paemen, L
    Opdenakker, G
    Newcombe, J
    [J]. JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 1996, 55 (12) : 1194 - 1204
  • [9] Plasminogen activators and matrix metalloproteases, mediators of extracellular proteolysis in inflammatory demyelination of the central nervous system
    Cuzner, ML
    Opdenakker, G
    [J]. JOURNAL OF NEUROIMMUNOLOGY, 1999, 94 (1-2) : 1 - 14
  • [10] GALLIS ZS, 1994, J CLIN INVEST, V94, P2493